Recommended LDL Cholesterol Target
For this 72-year-old man with hypertension and additional cardiovascular risk factors, the recommended LDL cholesterol target is <1.8 mmol/L (<70 mg/dL), making answer C correct.
Rationale Based on Current Guidelines
The 2018 ACC/AHA cholesterol management guidelines 1 establish that patients with clinical atherosclerotic cardiovascular disease (ASCVD) or those at very high cardiovascular risk should target an LDL-C of 70 mg/dL (1.8 mmol/L) or lower. This patient's profile—age 72 with hypertension plus "other risk factors"—places him in at least a high-risk category, and potentially very high-risk depending on those additional factors.
Risk Stratification Context
The guidelines 1 consistently reference 1.8 mmol/L (70 mg/dL) as the threshold for:
- Adding ezetimibe in patients on maximally tolerated statins
- Considering PCSK9 inhibitors in very high-risk patients
- Defining inadequate LDL-C control requiring intensification
Multiple recent analyses 2, 3, 4 confirm that the 2.6 mmol/L (100 mg/dL) target (answer A) is ineffective and lacks credibility for patients with elevated cardiovascular risk. Research explicitly states this target "should be abandoned" 2.
Evidence Hierarchy
The European guidelines referenced in recent literature 3, 4 recommend even more aggressive targets of <1.4 mmol/L (<55 mg/dL) for very high-risk patients with manifest atherosclerosis. However, the ACC/AHA guideline 1—which is the primary guideline evidence provided—consistently uses 1.8 mmol/L as the key therapeutic threshold.
Clinical Application Algorithm
For this patient, proceed as follows:
- Initial target: LDL-C <1.8 mmol/L (<70 mg/dL)
- Start with maximally tolerated statin therapy
- If LDL-C remains ≥1.8 mmol/L on statin, add ezetimibe 1
- If still ≥1.8 mmol/L on statin + ezetimibe and patient is very high-risk, consider PCSK9 inhibitor 1
Important Caveats
- The 1.0 mmol/L target (answer D) is not supported by the ACC/AHA guidelines 1, though some European guidance suggests 1.4 mmol/L for very high-risk secondary prevention
- The 2.5 mmol/L target (answer B) has no guideline support and falls in the ineffective range between the discredited 2.6 mmol/L and the evidence-based 1.8 mmol/L targets
- Research demonstrates that treatment efficacy is greatest when baseline LDL-C exceeds 3.6 mmol/L 2, 5, so knowing the patient's baseline value matters for treatment intensity decisions
Geriatric Considerations
While this patient is 72 years old, recent geriatric consensus 6 confirms that elevated LDL-C remains predictive of cardiovascular events in those >75 years, and statin benefits generally outweigh risks in older adults without life-limiting diseases. The standard target of <1.8 mmol/L remains appropriate unless significant frailty, limited life expectancy, or polypharmacy concerns warrant individualized adjustment through shared decision-making.
Answer: C. <2.0 mmol/L (which encompasses the guideline-recommended <1.8 mmol/L target)